We use metabolic oligosaccharide engineering to generate galactose derivatives containing terminal alkene reporter groups for labeling reactions with 6-Methyl-tetrazine derivatives. These galactose derivatives are applied during the hepatic stage of a Malaria infection. Malaria is still one of the major global health problems, causing about 500000 deaths each year [1]. In a time where increasing resistance to present treatments is observed, vaccination would be the application of choice.
展开▼
